Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$335K Buy
926
+52
+6% +$17.8K 0.11% 125
2026
Q1
$308K Buy
874
+193
+28% +$68.8K 0.12% 121
2025
Q4
$223K Buy
+681
New +$216K 0.09% 163
2025
Q2
Sell
-735
Closed -$229K 140
2025
Q1
$229K Buy
+735
New +$217K 0.13% 129
2024
Q4
Sell
-807
Closed -$260K 143
2024
Q3
$260K Buy
807
+33
+4% +$10.8K 0.13% 102
2024
Q2
$242K Buy
774
+24
+3% +$7.05K 0.12% 104
2024
Q1
$213K Buy
750
+53
+8% +$15.5K 0.1% 118
2023
Q4
$201K Buy
+697
New +$190K 0.1% 119

Other funds holding AMGN

Traveka Wealth's AMGN Position: Q2 2026 in Review

Traveka Wealth increased its Amgen (AMGN) stake by 5.9% in Q2 2026, buying an estimated $17.8K and bringing the position to 926 shares worth $335K. The position accounts for 0.11% of the portfolio, ranked #125.

Traveka Wealth first reported a position in AMGN in Q4 2023 and has held it in 8 quarters since. 1,625 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Traveka Wealth held 926 shares of Amgen worth $335K as of Q2 2026.
  • Traveka Wealth bought 52 Amgen shares in Q2 2026, an estimated $17.8K.
  • Amgen made up 0.11% of Traveka Wealth's portfolio in Q2 2026, its #125 holding.
  • Traveka Wealth first reported a position in Amgen in Q4 2023 and has held it in 8 quarters since.
  • 1,625 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Traveka Wealth's 13F filing for Q2 2026, filed 21 Jul 2026.